U.S. FDA panel split over approval of Durect's non-opioid painkiller - (This is Money via NewsPoints Desk)

  • An FDA advisory panel voted 6 to 6 on whether to recommend approval of Durect's experimental non-opioid analgesic Posimir, as reported on This is Money.

  • Posimir is a reformulated version of the anesthetic bupivacaine that aims to provide pain relief for up to three days after surgery.

To read more NewsPoints articles, click here.